Close Menu

Warnex Medical Laboratories

NEW YORK (GenomeWeb News) – Luminex's board of directors has authorized the firm to repurchase up to the lesser of $22.5 million worth or 900,000 shares of the company's outstanding common stock. The repurchase program is scheduled to expire Dec.

NEW YORK (GenomeWeb News) – Warnex announced today a binding agreement to sell its Bioanalytical Services division to contract research organization Biotrial Research for C$6 million (US$6 million).

NEW YORK (GenomeWeb News) – Warnex today said that it has signed a new credit facility with Persistence Capital Partners, replacing an existing credit facility with Accord Financial.

NEW YORK (GenomeWeb News) – Warnex today announced it has completed the sale of its Analytical Services division to Neopharm Labs.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Warnex said this week that the conversion of debentures into shares of the company will provide Persistence Capital Partners with a nearly 52 percent stake in the firm.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Warnex today said that it has inked an agreement with an unnamed private company to purchase Warnex's Analytical Services division for more than C$1.1 million (US$1.1 million).

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Warnex announced that it has sold its medical laboratories division to Gamma-Dynacare Medical Laboratories for C$7.5 million (US$7.3 million).

Pages

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.